Economic Burden of Chronic Obstructive Pulmonary Disease
- 83 Downloads
The incidence, morbidity and mortality of chronic obstructive pulmonary disease (COPD) is rising throughout the world. The total economic cost of COPD in the US in 1993 was estimated to be over $US15.5 billion, with $US6.1 billion for hospitalisation, $US4.4 billion for physician and other fees, $US2.5 billion for drugs, $US1.5 billion for nursing home care and $US1.0 billion for home care. Office visits, hospital outpatient visits and emergency department visits accounted for 17.3% of the direct costs for COPD in the US. When stratified by severity, COPD treatment costs strongly correlate with disease severity. The American Thoracic Society, the European Respiratory Society and the British Thoracic Society have developed guidelines for the pharmacological treatment of COPD. However, the guidelines establish inhaled bronchodilators (anticholinergic agents and β2-adrenergic agonists) as the mainstay of therapy for patients with COPD. The guidelines were not based on cost analyses and thus are not a priori cost-effective guidelines.
Since the publication of these guidelines, several new pharmacological products have been approved for use in patients with COPD including a combination of an anticholinergic and selective β2-adrenergic agonist [ipratropium/salbutamol (albuterol)] and a long-acting β2-adrenergic agonist (salmeterol). Both products are effective bronchodilators in COPD. The purpose of this report is to place these new agents in an updated pharmacological guideline scheme, utilising recently published data on clinical efficacy as well as pharmacoeconomics. The annualised healthcare costs were computed to be $US788/patient/year for the combination ipratropium/salbutamol inhaler and $US1059/patient/year for salmeterol (1999 values). Based upon an improved understanding of the complexity of COPD, the response of patients to newer bronchodilators (given individually or in combination), and recent pharmacoeconomic data for COPD treatment, a new treatment algorithm with associated costs is proposed. The use of an algorithm, based on medical and pharmacoeconomic data, will improve lung function in patients with COPD, improve patient satisfaction (e.g. quality of life, dyspnoea) and outcomes (e.g. exacerbations). It will also result in a positive effect on healthcare costs.
KeywordsChronic Obstructive Pulmonary Disease Salbutamol Salmeterol Ipratropium American Thoracic Society
- 1.Singh GK, Matthews TJ, Clarke SC, et al. Annual summary of births, marriages, divorces and deaths: United States, 1994; monthly vital statistics report. Vol. 43. No. 13. Hyattsville (MD): National Center for Health Statistics, 1994Google Scholar
- 3.National Heart, Lung, and Blood Institute. Morbidity & mortality: 1998 chartbook on cardiovascular, lung, and blood diseases. Hyattsville (MD): US Department of Health and Human Services, Public Health Service, 1998 OctGoogle Scholar
- 4.Center for Disease Control and Prevention/National Center for Health Statistics. Discharge summary annual survey 1998. Hyattsville (MD): Center for Disease Control and Prevention, 1998Google Scholar
- 5.Benson V, Marano MA. Current estimates from the National Health Interview Survey, 1995. National Center for Health Statistics. Vital Health Stat 1998; 10 (199): 1–428Google Scholar
- 6.American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S78–S121Google Scholar
- 10.COPD Guideline Group of the Standards of Care of the British Thoracic Society. Thorax 1997; 52 Suppl. 5: S1–S28Google Scholar
- 18.Price-Check PC: version 2.16 [CD-ROM]. St Louis (MO): Medi-Span, 1998Google Scholar
- 19.Price-Check PC: version 2.16 [CD-ROM]. St Louis (MO): Medi-Span, 1999Google Scholar
- 24.Niser NM, Walshaw JE, Earis MG, et al. Assessment of reversibility of airway obstruction in patients with chronic airways obstruction. Thorax 1990;: 190–4Google Scholar